Additional research found that low TIL levels in initial biopsies were associated with a low chance of achieving pCR in HER2+ breast cancer patients treated with trastuzumab plus pertuzumab and chemotherapy in the neoadjuvant setting [238,239]. The gene discussed is ERBB2; the disease is breast carcinoma.